Characteristics of 174 Fludarabine-Treated CLL Patients
| Median age (yr) (range) | 61 (25-84) |
| Male/female | 110/64 |
| Rai | |
| I/II | 59/49 (108) |
| III/IV | 38/28 (66) |
| Time from diagnosis to Rx | 9 mo (0-346) |
| B symptoms | 16 (9%) |
| Performance status (0, 1, 2) | (93, 75, 6) |
| WBC ×103/mL (range) | 61.7 (5.1-430.0) |
| Prior infection | 12 (7%) |
| Median age (yr) (range) | 61 (25-84) |
| Male/female | 110/64 |
| Rai | |
| I/II | 59/49 (108) |
| III/IV | 38/28 (66) |
| Time from diagnosis to Rx | 9 mo (0-346) |
| B symptoms | 16 (9%) |
| Performance status (0, 1, 2) | (93, 75, 6) |
| WBC ×103/mL (range) | 61.7 (5.1-430.0) |
| Prior infection | 12 (7%) |